Post-COVID Trajectory of Pentraxin 3 Plasma Levels Over 6 Months and Their Association with the Risk of Developing Post-Acute Depression and Anxiety-Reference-Cited by-同舟云学术

Post-COVID Trajectory of Pentraxin 3 Plasma Levels Over 6 Months and Their Association with the Risk of Developing Post-Acute Depression and Anxiety

Published:2024-04-24 Issue:6 Volume:38 Page:459-472
ISSN:1172-7047
Container-title:CNS Drugs
language:en
Short-container-title:CNS Drugs

Author:

De Lorenzo Rebecca,Mazza Mario G.,Sciorati Clara,Leone Roberto,Scavello Francesco,Palladini Mariagrazia,Merolla Aurora,Ciceri Fabio,Bottazzi Barbara,Garlanda Cecilia,Benedetti Francesco,Rovere-Querini Patrizia,Manfredi Angelo A.

Funder

Philanthropic donation by Dolce & Gabbana fashion

Ministero della Salute

NextGeneration EU-MUR PNRR

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40263-024-01081-4.pdf

Reference76 articles.

1. Carfì A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603–5. https://doi.org/10.1001/jama.2020.12603.

2. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601–15. https://doi.org/10.1038/s41591-021-01283-z.

3. Huang S, Zhou Z, Yang D, Zhao W, Zeng M, Xie X, et al. Persistent white matter changes in recovered COVID-19 patients at the 1-year follow-up. Brain. 2022;145(5):1830–8.

4. Venkatesan P. NICE guideline on long COVID. Lancet Respir Med. 2021;9(2):129. https://doi.org/10.1016/S2213-2600(21)00031-X.

5. Nasserie T, Hittle M, Goodman SN. Assessment of the frequency and variety of persistent symptoms among patients With COVID-19: a systematic review. JAMA Netw Open. 2021;4(5): e2111417. https://doi.org/10.1001/jamanetworkopen.2021.11417.